Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
Key Points
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share.
This transaction impacted 13.46% of Long’s direct Common Stock holdings, reducing his position to 96,412 shares.
The sale was executed directly (no indirect entities involved), via option exercise immediately followed by sale.
- 10 stocks we like better than Septerna ›
Daniel D. Long, SVP, Drug Discovery at Septerna (NASDAQ:SEPN), reported the exercise and immediate sale of 15,000 shares of Common Stock on June 22, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares traded (direct) | 15,000 |
| Transaction value | ~$533,000 |
| Post-transaction shares (direct) | 96,412 |
| Post-transaction value (direct ownership) | ~$3.36 million |
Transaction value based on SEC Form 4 weighted average purchase price ($35.51); post-transaction value based on June 22, 2026, market close.
Key questions
- What was the structure and context of this transaction?
This was a derivative-based transaction involving the exercise of 15,000 options for Common Stock, which were sold immediately. - How does this sale affect Long’s direct ownership in Septerna?
The transaction reduced Long's direct Common Stock holdings by 13.46%, from 111,412 to 96,412 shares, with no change to indirect holdings (which remain at zero). - What continuing exposure does Long have to Septerna equity?
In addition to 96,412 directly held Common shares, Long retains continued exposure to Septerna through unexercised stock options representing about 36,000 shares. - Does historical trading data indicate a pattern or capacity constraint?
While Long’s direct holdings have declined by 16.1% since October 2024, the larger trade size here reflects the capacity created by prior administrative adjustments and available option grants, rather than a discretionary increase in selling.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $1.59 billion |
| Revenue (TTM) | $72.25 million |
| Net income (TTM) | -$36.04 million |
| 1-year price change | 236.8% |
* 1-year performance calculated using June 27, 2026, as the reference date.
Company snapshot
- Develops oral small molecule therapeutics targeting G protein-coupled receptors (GPCRs), with lead programs in endocrinology, immunology, and metabolic diseases.
- Generates revenue through licensing agreements and collaborations, notably with Novo Nordisk (NYSE:NVO), and advances proprietary clinical-stage drug candidates.
- Targets healthcare providers and pharmaceutical partners addressing unmet needs in rare endocrine, immunological, and metabolic disorders.
Septerna is a clinical-stage biotechnology company specializing in the discovery and development of oral small-molecule therapies focused on GPCR targets. The company leverages a robust pipeline and strategic collaborations to advance treatments for complex diseases such as hypoparathyroidism, chronic urticaria, and metabolic disorders. Septerna's integrated approach and partnerships position it to address significant therapeutic gaps in the healthcare market.
What this transaction means for investors
There are thousands of reasons for insiders to sell their shares, and most of them aren’t related to their level of confidence. It looks like Long is supplementing his income by exercising the options he receives, rather than an insider trying to exit a bad investment. He finished the transaction with over 96,000 shares and over 35,000 stock options.
Septerna is working with Novo Nordisk to discover, develop, and commercialize multiple treatment candidates for obesity, type 2 diabetes, and other cardiometabolic diseases. Its drug development platform targets G-protein-coupled receptors to treat various diseases. So far, Novo Nordisk hasn’t advanced any partnered candidates into clinical-stage testing.
Earlier this year, the company’s Chief Medical Officer announced his departure.
In March, the company presented positive phase 1 trial results for SEP-631. An upcoming phase 2 study with folks who suffer from chronic spontaneous urticaria, or hives, is expected to begin later this year.
Should you buy stock in Septerna right now?
Before you buy stock in Septerna, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Septerna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $398,052!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,181,688!*
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 29, 2026.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
